Brief: Simcere Pharmaceutical Receives Clinical Trial Approval For SIM0689 From China's NMPA
12/06/2026 14:01
BRIEF-Simcere Pharmaceutical Receives Clinical Trial Approval For SIM0689 From China's NMPA June 12 (Reuters) - Simcere Pharmaceutical Group Ltd 2096.HK:
RECEIVES CLINICAL TRIAL APPROVAL FOR SIM0689 FROM NATIONAL MEDICAL PRODUCTS ADMINISTRATION
Further company coverage: 2096.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Simcere Pharmaceutical
See all newsBrief: Simcere Pharmaceutical Receives Clinical Trial Approval For SIM0689 From China's NMPA
Brief: Simcere Pharmaceutical Enters Exclusive Promotion Service Agreement With Primegenx Therapeutics
Brief: Simcere Pharmaceutical Receives NMPA China Clinical Trial Approval For SIM0613
Brief: Simcere Pharmaceutical Says NDA For Rademikibart Accepted By NMPA
Brief: Simcere Pharma Withdraws NDA For Rademikibart, Expects To Resubmit Within April 2026